{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T20:29:33Z","timestamp":1776198573238,"version":"3.50.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T00:00:00Z","timestamp":1654905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Molecular Autism"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Autism spectrum disorder (ASD) is a common and heterogeneous neurodevelopmental condition that is characterized by the core symptoms of social communication difficulties and restricted and repetitive behaviors. At present, there is an unmet medical need for therapies to ameliorate these core symptoms in order to improve quality of life of autistic individuals. However, several challenges are currently faced by the ASD community relating to the development of pharmacotherapies, namely in the conduct of clinical trials. Balovaptan is a V1a receptor antagonist that has been investigated to improve social communication difficulties in individuals with ASD. In this viewpoint, we draw upon our recent first-hand experiences of the balovaptan clinical development program to describe current challenges of ASD trials.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion points<\/jats:title>\n                <jats:p>The balovaptan trials were conducted in a wide age range of individuals with ASD with the added complexities associated with international trials. When summarizing all three randomized trials of balovaptan, a placebo response was observed across several outcome measures. Placebo response was predicted by greater baseline symptom severity, online recruitment of participants, and less experienced or non-academic trial sites. We also highlight challenges relating to selection of outcome measures in ASD, the impact of baseline characteristics, and the role of expectation bias in influencing trial results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Taken together, the balovaptan clinical development program has advanced our understanding of the key challenges facing ASD treatment research. The insights gained can be used to inform and improve the design of future clinical trials with the collective aim of developing efficacious therapies to support individuals with ASD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13229-022-00505-6","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T12:03:34Z","timestamp":1654949014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-7398","authenticated-orcid":false,"given":"Suma","family":"Jacob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3455-9887","authenticated-orcid":false,"given":"Evdokia","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4196-0596","authenticated-orcid":false,"given":"Eric","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7501-7865","authenticated-orcid":false,"given":"Roger","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-2079","authenticated-orcid":false,"given":"Nora","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9816-1598","authenticated-orcid":false,"given":"Linmarie","family":"Sikich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7738-8344","authenticated-orcid":false,"given":"Russell","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-7451","authenticated-orcid":false,"given":"Declan","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0370-0777","authenticated-orcid":false,"given":"James","family":"McCracken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2144-7197","authenticated-orcid":false,"given":"Elizabeth","family":"Ashford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-8285","authenticated-orcid":false,"given":"Christopher","family":"Chatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3458-0117","authenticated-orcid":false,"given":"Susanne","family":"Clinch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7267-5774","authenticated-orcid":false,"given":"Janice","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6382-5072","authenticated-orcid":false,"given":"Kevin","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2388","authenticated-orcid":false,"given":"Lorraine","family":"Murtagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4119-6076","authenticated-orcid":false,"given":"Jana","family":"Noeldeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6349-1076","authenticated-orcid":false,"given":"Jeremy","family":"Veenstra-VanderWeele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,11]]},"reference":[{"key":"505_CR1","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1007\/s10803-020-04494-4","volume":"50","author":"PM Dietz","year":"2020","unstructured":"Dietz PM, Rose CE, McArthur D, Maenner M. National and state estimates of adults with autism spectrum disorder. J Autism Dev Disord. 2020;50:4258\u201366.","journal-title":"J Autism Dev Disord"},{"key":"505_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12264-017-0100-y","volume":"33","author":"A Masi","year":"2017","unstructured":"Masi A, DeMayo MM, Glozier N, Guastella AJ. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull. 2017;33:183\u201393.","journal-title":"Neurosci Bull"},{"key":"505_CR3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/aur.1965","volume":"11","author":"D Mason","year":"2018","unstructured":"Mason D, McConachie H, Garland D, Petrou A, Rodgers J, Parr JR. Predictors of quality of life for autistic adults. Autism Res. 2018;11:1138\u201347.","journal-title":"Autism Res"},{"key":"505_CR4","unstructured":"Centers for Disease Control and Prevention. Treatment and Intervention Services for Autism Spectrum Disorder. https:\/\/www.cdc.gov\/ncbddd\/autism\/treatment.html. Accessed 9 Dec 2021."},{"key":"505_CR5","first-page":"18","volume":"46","author":"M DeFilippis","year":"2016","unstructured":"DeFilippis M, Wagner KD. Treatment of autism spectrum disorder in children and adolescents. Psychopharmacol Bull. 2016;46:18\u201341.","journal-title":"Psychopharmacol Bull"},{"key":"505_CR6","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/MOP.0b013e32834cf082","volume":"23","author":"G Dawson","year":"2011","unstructured":"Dawson G, Burner K. Behavioral interventions in children and adolescents with autism spectrum disorder: a review of recent findings. Curr Opin Pediatr. 2011;23:616\u201320.","journal-title":"Curr Opin Pediatr"},{"key":"505_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/1362361307098516","volume":"13","author":"LA Vismara","year":"2009","unstructured":"Vismara LA, Colombi C, Rogers SJ. Can one hour per week of therapy lead to lasting changes in young children with autism? Autism. 2009;13:93\u2013115.","journal-title":"Autism"},{"key":"505_CR8","doi-asserted-by":"publisher","first-page":"eaat7838","DOI":"10.1126\/scitranslmed.aat7838","volume":"11","author":"F Bolognani","year":"2019","unstructured":"Bolognani F, Del Valle Rubido, Squassante L, Wandel C, Derks M, Murtagh L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019;11:eaat7838.","journal-title":"Sci Transl Med"},{"key":"505_CR9","doi-asserted-by":"publisher","first-page":"eaau7356","DOI":"10.1126\/scitranslmed.aau7356","volume":"11","author":"KJ Parker","year":"2019","unstructured":"Parker KJ, Oztan O, Libove RA, Mohsin N, Karhson DS, Sumiyoshi RD, et al. A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med. 2019;11:eaau7356.","journal-title":"Sci Transl Med"},{"key":"505_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3389\/fnbeh.2019.00143","volume":"13","author":"NF Kompier","year":"2019","unstructured":"Kompier NF, Keysers C, Gazzola V, Lucassen PJ, Krugers HJ. Early life adversity and adult social behavior: focus on arginine vasopressin and oxytocin as potential mediators. Front Behav Neurosci. 2019;13:143.","journal-title":"Front Behav Neurosci"},{"key":"505_CR11","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1038\/npp.2016.232","volume":"42","author":"D Umbricht","year":"2017","unstructured":"Umbricht D, Del Valle RM, Hollander E, McCracken JT, Shic F, Scahill L, et al. A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder. Neuropsychopharmacol. 2017;42:1914\u201323.","journal-title":"Neuropsychopharmacol"},{"key":"505_CR12","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1021\/jm501745f","volume":"58","author":"H Ratni","year":"2015","unstructured":"Ratni H, Rogers-Evans M, Bissantz C, Grundschober C, Moreau J-L, Schuler F, et al. Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenic and scaffold hopping approach. J Med Chem. 2015;58:2275\u201389.","journal-title":"J Med Chem"},{"key":"505_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","volume":"9","author":"S Jacob","year":"2022","unstructured":"Jacob S, Veenstra-Vanderweele J, Murphy D, McCracken J, Smith J, Sanders K, et al. Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry. 2022;9:199\u2013210.","journal-title":"Lancet Psychiatry"},{"key":"505_CR14","first-page":"S262","volume":"59","author":"E Hollander","year":"2020","unstructured":"Hollander E, Jacob S, Jou RJ, McNamara N, Sikich L, Tobe R, et al. A phase 2 randomized controlled trial of balovaptan in pediatric participants with autism spectrum disorder. JAACAP. 2020;59:S262\u20133.","journal-title":"JAACAP"},{"key":"505_CR15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s13063-021-05454-8","volume":"22","author":"SH Haflioadottir","year":"2021","unstructured":"Haflioadottir SH, Juhl CB, Nielsen SM, Henriksen M, Harries IA, Bliddal H, et al. Placebo response and effect in randomized clinical trials: meta-research with focus on contextual effects. Trials. 2021;22:493.","journal-title":"Trials"},{"key":"505_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000490354","volume":"87","author":"AWM Evers","year":"2018","unstructured":"Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Bendetti F, et al. Implications of placebo and nocebo effects for clinical practice: expert consensus. Psychother Psychosom. 2018;87:204\u201310.","journal-title":"Psychother Psychosom"},{"key":"505_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/JCP.0b013e3181d20912","volume":"30","author":"KA Kobak","year":"2010","unstructured":"Kobak KA, Leuchter A, DeBrota D, Engelhardt N, Williams JBW, Cook IA, et al. Site versus centralized raters in a clinical depression trial\u2014impact on patient selection and placebo response. J Clin Psychopharmacol. 2010;30:193\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"505_CR18","first-page":"1","volume":"27","author":"JB Williams","year":"2012","unstructured":"Williams JB, Popp D, Kobak KA, Detke MJ. The power of expectation bias. Eur Psychiatry. 2012;27:1.","journal-title":"Eur Psychiatry"},{"key":"505_CR19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13229-020-00372-z","volume":"11","author":"S Siafis","year":"2020","unstructured":"Siafis S, Ciray O, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, et al. Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Mol Autism. 2020;11:66.","journal-title":"Mol Autism"},{"key":"505_CR20","first-page":"e2125531","volume":"4","author":"BDM Jones","year":"2021","unstructured":"Jones BDM, Razza LB, Weissman CR, Karbi J, Vine J. Magnitude of the placebo response across treatment modalities used for treatment-resistent depression in adults\u2014a systematic review and meta-analysis. JAMA Psychiat. 2021;4:e2125531.","journal-title":"JAMA Psychiat"},{"key":"505_CR21","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","volume":"170","author":"BR Rutherford","year":"2013","unstructured":"Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170:723\u201333.","journal-title":"Am J Psychiatry"},{"key":"505_CR22","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1089\/cap.2015.0192","volume":"26","author":"ET Dobson","year":"2016","unstructured":"Dobson ET, Strawn JR. Placebo response in pediatric anxiety disorders: implications for clinical trial design and interpretation. J Child Adolesc Psychopharmacol. 2016;26:686\u201393.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"505_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","volume":"71","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials\u2014a meta-analysis. JAMA Psychiat. 2014;71:1409\u201321.","journal-title":"JAMA Psychiat"},{"key":"505_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/acps.12960","volume":"139","author":"K Kubo","year":"2019","unstructured":"Kubo K, Fleichhacker WW, Suzuki T, Yasui-Furukori N, Mimura M, Uchida H. Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCTs. Acta Psychiatr Scand. 2019;139:108\u201316.","journal-title":"Acta Psychiatr Scand"},{"key":"505_CR25","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3390\/brainsci10090629","volume":"10","author":"S Luu","year":"2020","unstructured":"Luu S, Province H, Berry-Kravis E, Hagerman R, Hessl D, Vaidya D, et al. Response to placebo in Fragile X syndrome clinical trials: an initial analysis. Brain Sci. 2020;10:629.","journal-title":"Brain Sci"},{"key":"505_CR26","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/npp.2012.153","volume":"37","author":"BW Dunlop","year":"2012","unstructured":"Dunlop BW, Thase ME, Wun CC, Fayyad R, Guico-Pabia CJ, Musgnung J, et al. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology. 2012;37:2830\u20136.","journal-title":"Neuropsychopharmacology"},{"key":"505_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1093\/schbul\/sbx192","volume":"45","author":"D Fraugas","year":"2018","unstructured":"Fraugas D, Diaz-Caneja CM, Pina-Camacho L, Umbricht D, Arango C. Predictors of placebo response in pharmacological clinical trials of negative symptoms in schizophrenia: a meta-regression analysis. Schizophr Bull. 2018;45:57\u201368.","journal-title":"Schizophr Bull"},{"key":"505_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00787-018-1244-7","volume":"29","author":"R Meister","year":"2020","unstructured":"Meister R, Abbas M, Antel J, Peters T, Pan Y, Bingel U, et al. Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis. Eur Child Adolesc Psychiatry. 2020;29:253\u201373.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"505_CR29","doi-asserted-by":"publisher","first-page":"e22179","DOI":"10.2196\/22179","volume":"22","author":"M Brogger-Mikkelsen","year":"2020","unstructured":"Brogger-Mikkelsen M, Ali Z, Zibert JR, Andersen AD, Thomsen SF. Online patient recruitment in clinical trials: systematic review and meta-analysis. J Med Internet Res. 2020;22:e22179.","journal-title":"J Med Internet Res"},{"key":"505_CR30","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1001\/jamapediatrics.2013.2698","volume":"167","author":"BH King","year":"2013","unstructured":"King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013;167:1045\u201352.","journal-title":"JAMA Pediatr"},{"key":"505_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5607\/en.2015.24.4.257","volume":"24","author":"H Yoo","year":"2015","unstructured":"Yoo H. Genetics of autism spectrum disorder: current status and possible clinical applications. Exp Neurobiol. 2015;24:257\u201372.","journal-title":"Exp Neurobiol"},{"key":"505_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fnmol.2018.00027","volume":"11","author":"I Cataldo","year":"2018","unstructured":"Cataldo I, Azhari A, Esposito G. A review of oxytocin and arginine-vasopressin receptors and their modulation of autism spectrum disorder. Front Mol Neurosci. 2018;11:27.","journal-title":"Front Mol Neurosci"},{"key":"505_CR33","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13229-017-0145-9","volume":"8","author":"T Charman","year":"2017","unstructured":"Charman T, Loth E, Tillmann J, Crawley D, Wooldridge C, Goyard D, et al. The EU-AIMS Longitudinal European Autism Project (LEAP): clinical characterisation. Mol Autism. 2017;8:27.","journal-title":"Mol Autism"},{"key":"505_CR34","doi-asserted-by":"publisher","unstructured":"Stavropoulos KKM, Baker E. Priming the pathway: combining oxytocin and behavioral intervention to improve outcomes in autism spectrum disorder: In: Wu W, Kostoglou-Athanassiou I, editors. Oxytocin and health [internet]. London: IntechOpen; 2021. https:\/\/www.intechopen.com\/chapters\/76208. https:\/\/doi.org\/10.5772\/intechopen.96859","DOI":"10.5772\/intechopen.96859"},{"key":"505_CR35","doi-asserted-by":"publisher","first-page":"e640","DOI":"10.1038\/tp.2015.143","volume":"5","author":"A Masi","year":"2015","unstructured":"Masi A, Lampit A, Glozier N, Hickie IB, Guastella AJ. Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis. Transl Psychiatry. 2015;5:e640.","journal-title":"Transl Psychiatry"},{"key":"505_CR36","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/1362361314542955","volume":"19","author":"EJ Anagnostou","year":"2015","unstructured":"Anagnostou EJ, Jones N, Huerta M, Halladay AK, Wang P, Scahill L, et al. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism. 2015;19:622\u201336.","journal-title":"Autism"},{"key":"505_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mpr.1466","volume":"24","author":"TS Brugha","year":"2015","unstructured":"Brugha TS, Doos L, Tempier A, Einfeld S, Howlin P. Outcome measures in intervention trials for adults with autism spectrum disorders; a systematic review of assessments of core autism features and associated emotional and behavioural problems. Int J Methods Psychiatr Res. 2015;24:99\u2013115.","journal-title":"Int J Methods Psychiatr Res"},{"key":"505_CR38","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s10803-013-1798-7","volume":"43","author":"EE Bolte","year":"2013","unstructured":"Bolte EE, Diehl JJ. Measurement tools and target symptoms\/skills used to assess treatment response for individuals with autism spectrum disorder. J Autism Dev Disord. 2013;43:2491\u2013501.","journal-title":"J Autism Dev Disord"},{"key":"505_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pnpbp.2009.09.012","volume":"34","author":"S Akhondzadeh","year":"2010","unstructured":"Akhondzadeh S, Fallah J, Mohammadi MR, Imani R, Mohammadi M, Salehi B, et al. Double-blind placebo-controlled trial of pentoxifylline added to risperidone: effects on aberrant behavior in children with autism. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:32\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"505_CR40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1362361313510069","volume":"19","author":"L Scahill","year":"2015","unstructured":"Scahill L, Aman MG, Lecavalier L, Halladay AK, Bishop SL, Bodfish JW, et al. Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder. Autism. 2015;19:38\u201352.","journal-title":"Autism"},{"key":"505_CR41","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s10803-015-2562-y","volume":"46","author":"E Moricke","year":"2016","unstructured":"Moricke E, Buitelaar JK, Rommelse NNJ. Do we need multiple informants when assessing autistic traits? The degree of report bias on offspring, self, and spouse ratings. J Autism Dev Disord. 2016;46:164\u201375.","journal-title":"J Autism Dev Disord"},{"key":"505_CR42","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/aur.2026","volume":"11","author":"RM Del Valle","year":"2018","unstructured":"Del Valle RM, McCracken JT, Hollander E, Shic F, Noeldeke J, Boak L, et al. In search of biomarkers for autism spectrum disorder. Autism Res. 2018;11:1567\u201379.","journal-title":"Autism Res"},{"key":"505_CR43","first-page":"135","volume":"16","author":"A Klin","year":"2018","unstructured":"Klin A. Biomarkers in autism spectrum disorder: challenges, advances, and the need for biomarkers of relevance to public health. Focus (Am Psychiatr Publ). 2018;16:135\u201342.","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"505_CR44","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/frobt.2019.00132","volume":"6","author":"AL Georgescu","year":"2019","unstructured":"Georgescu AL, Koehler JC, Weiske J, Vogeley K, Koutsouleris N, Falter-Wagner C. Machine learning to study social interaction difficulties in ASD. Front Robot AI. 2019;6:132.","journal-title":"Front Robot AI"},{"key":"505_CR45","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1080\/13854046.2020.1737236","volume":"35","author":"RA Baksh","year":"2021","unstructured":"Baksh RA, Abrahams S, Bertlich M, Cameron R, Jany S, Dorrian T, et al. Social cognition in adults with autism spectrum disorders: validation of the Edinburgh Social Cognition Test (ESCoT). Clin Neuropsychol. 2021;35:1275\u201393.","journal-title":"Clin Neuropsychol"},{"key":"505_CR46","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fnint.2020.00016","volume":"14","author":"JC McPartland","year":"2020","unstructured":"McPartland JC, Bernier RA, Jeste SS, Dawson G, Nelson CA, Chawarska K, et al. The Autism Biomarkers Consortium for Clinical Trials (ABC-CT): scientific context, study design, and progress toward biomarker qualification. Front Integr Neurosci. 2020;14:16.","journal-title":"Front Integr Neurosci"},{"key":"505_CR47","doi-asserted-by":"publisher","first-page":"eaat9223","DOI":"10.1126\/scitranslmed.aat9223","volume":"11","author":"\u0160 Holiga","year":"2019","unstructured":"Holiga \u0160, Hipp JF, Chatham CH, Garces P, Spooren W, D\u2019Ardhuy XL, et al. Patients with autism spectrum disorders display reproducible functional connectivity alterations. Sci Transl Med. 2019;11:eaat9223.","journal-title":"Sci Transl Med."},{"key":"505_CR48","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/cpt.1638","volume":"107","author":"HG Eichler","year":"2020","unstructured":"Eichler HG, Koenig F, Arlett P, Enzmann H, Humphreys A, Petavy F, et al. Are novel, nonrandomized analytic methods fit for decision making? The need for prospective, controlled, and transparent validation. Clin Pharmacol Ther. 2020;107:773\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"505_CR49","unstructured":"ClinicalTrials.gov. NCT03611075 (2018). A Study to Evaluate Scales for Repetitive and Restricted Behaviors in Children, Adolescents, and Adults With Autism Spectrum Disorder (ASD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03611075. Accessed 9 Dec 2021."},{"key":"505_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41746-019-0090-4","volume":"2","author":"A Coravos","year":"2019","unstructured":"Coravos A, Khozin S, Mandl KD. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. NPJ Digit Med. 2019;2:14.","journal-title":"NPJ Digit Med"},{"key":"505_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41746-018-0024-6","volume":"1","author":"HL Egger","year":"2018","unstructured":"Egger HL, Dawson G, Hashemi J, Carpenter KLH, Espinosa S, Campbell K, et al. Automatic emotion and attention analysis of young children at home: a ResearchKit autism feasibility study. NPJ Digit Med. 2018;1:20.","journal-title":"NPJ Digit Med"},{"key":"505_CR52","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fnins.2019.00111","volume":"13","author":"SL Ness","year":"2019","unstructured":"Ness SL, Bangerter A, Manyakov NV, Lewin D, Boice M, Skalkin A, et al. An observational study with the Janssen Autism Knowledge Engine (JAKE\u00ae) in individuals with autism spectrum disorder. Front Neurosci. 2019;13:111.","journal-title":"Front Neurosci"},{"key":"505_CR53","unstructured":"O'Sullivan J, Nobbs D, Slater D, Kilchenmann T, Cheng WY, Murtagh L, et al. Remote assessment of ASD in clinical trials: automated analysis of natural conversation. Presented at the International Society for Autism Research (INSAR) Virtual Annual Meeting 2021. Abstract 446.017."},{"key":"505_CR54","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamapediatrics.2019.0285","volume":"173","author":"C Voss","year":"2019","unstructured":"Voss C, Schwartz J, Daniels J, Kline A, Haber N, Washington P, et al. Effect of wearable digital intervention for improving socialization in children with autism spectrum disorder: a randomized clinical trial. JAMA Pediatr. 2019;173:446\u201354.","journal-title":"JAMA Pediatr"},{"key":"505_CR55","doi-asserted-by":"publisher","first-page":"15","DOI":"10.29245\/2578-2959\/2018\/5.1166","volume":"2","author":"R Grzadzinski","year":"2018","unstructured":"Grzadzinski R, Lord C. Commentary: insights into the development of the Brief Observation of Social Communication Change (BOSCC). J Ment Health Clin Psychol. 2018;2:15\u20138.","journal-title":"J Ment Health Clin Psychol"},{"key":"505_CR56","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1176\/appi.ajp.2016.16020225","volume":"174","author":"BR Rutherford","year":"2017","unstructured":"Rutherford BR, Wall MM, Brown PJ, Choo T-H, Wager TD, Peterson BS, et al. Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J Psychiatry. 2017;174:135\u201342.","journal-title":"Am J Psychiatry"},{"key":"505_CR57","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fpsyt.2019.00713","volume":"10","author":"M Curcovic","year":"2019","unstructured":"Curcovic M, Kosec A. Significance of participants\u2019 expectations in managing the placebo effect in antidepressant research. Front Psychiatry. 2019;10:713.","journal-title":"Front Psychiatry"},{"key":"505_CR58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0140-6736(21)01541-5","volume":"399","author":"C Lord","year":"2022","unstructured":"Lord C, Charman T, Havdahl A, Carbone P, Anagnostou E, Boyd B, et al. The Lancet Commission on the future of care and clinical research in autism. Lancet. 2022;399:271\u2013334.","journal-title":"Lancet"},{"key":"505_CR59","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jclinepi.2021.11.007","volume":"142","author":"T Bigirumurame","year":"2022","unstructured":"Bigirumurame T, Uwimpuhwe G, Wason J. Sequential multiple assignment randomized trial studies should report all key components: a systematic review. J Clin Epidemiol. 2022;142:152\u201360.","journal-title":"J Clin Epidemiol"},{"key":"505_CR60","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/biom.12576","volume":"73","author":"Y Liu","year":"2017","unstructured":"Liu Y, Wang Y, Zeng D. Sequential multiple assignment randomization trials with enrichment design. Biometrics. 2017;73:378\u201390.","journal-title":"Biometrics"}],"container-title":["Molecular Autism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-022-00505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13229-022-00505-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-022-00505-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T13:10:25Z","timestamp":1654953025000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularautism.biomedcentral.com\/articles\/10.1186\/s13229-022-00505-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,11]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["505"],"URL":"https:\/\/doi.org\/10.1186\/s13229-022-00505-6","relation":{},"ISSN":["2040-2392"],"issn-type":[{"value":"2040-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,11]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SJ has received grant support from NIH and F. Hoffmann-La Roche Ltd and has attended advisory boards for Fraser, Minnesota Independence College & Community, and F. Hoffmann-La Roche Ltd. EA has received grant support from F. Hoffmann-La Roche Ltd and SynapDx; royalties from APPI, Springer, and Wiley; has acted as a consultant for Quadrant, F. Hoffmann-La Roche Ltd, and SynapDx; has received honorarium for a webinar from AIDE; has a patent on anxiety meter; and has received a study drug and in kind supports from AMO Pharma. EH has received research grants from the Department of Defense, Food and Drug Administration, GW Pharma, and F. Hoffmann-La Roche Ltd; and editorial stipends from Elsevier; and served on scientific advisory boards for GW Pharma and F. Hoffmann-La Roche Ltd. RJ\u2019s institution received payments for clinical trial agreements from Roche Translational & Clinical Research Center, Inc. and Genentech, Inc. NM has provided research support to F. Hoffmann-La Roche Ltd; and consulted for Shire; grant support has been received from Forest Research Institute, Genentech, Lundbeck, Pfizer, F. Hoffmann-La Roche Ltd, Shire, Sunovion, and Zynerba. LS has received funding from the National Institute of Child Health and Human Development; was paid by F. Hoffmann-La Roche Ltd as a clinical research site investigator for involvement in conducting the\u00a0VANILLA and aV1ation studies; has attended an advisory board for F. Hoffmann-La Roche Ltd; and has a patent pending for new formulation of intranasal oxytocin by Duke University; part of her salary is paid by the Duke Clinical Research Institute where she is providing thought leadership for trials sponsored by Tris Pharmaceuticals. RT has received grant support from Janssen and F. Hoffmann-La Roche Ltd; and has attended advisory boards for F. Hoffmann-La Roche Ltd. DM receives funding support from the EU\/EFPIA\/SFARI\/Autistica\/AUTISM SPEAKS Innovative Medicines Initiative 2 Joint Undertaking (AIMS-2-TRIALS Grant No. 777394); has received grant support from F Hoffmann-La Roche and Shire; royalties from Springer and Wiley; and has attended advisory boards for F Hoffmann-La Roche and Servier. JM has received research support from F. Hoffmann-La Roche Ltd; has attended advisory boards for GW Pharmaceuticals and F. Hoffmann-La Roche Ltd; and was a consultant for Octopharma and TRIS Pharmaceuticals. JV-VW has received research support from NIH, the Simons Foundation, Health Canada, F. Hoffmann-La Roche Ltd, Janssen, Acadia, and Zynerba; royalties from Springer and Wiley; honoraria for lectures at the American Academy of Child and Adolescent Psychiatry, Karolinska Institute, Mount Sinai, National Institute of Neurological Disease and Stroke, Florida Atlantic University, UCLA, Stanford University, Child Mind Institute, and Pennsylvania State University; has attended advisory boards for Roche; serves on the medical and\/or scientific advisory boards for Autism Speaks, the Simons Foundation Autism Research Initiative, and the Brain Behavior Research Foundation; and serves as the co-chair of the Autism and Intellectual Disability Committee for the American Academy of Child and Adolescent Psychiatry. EAs is an employee of F. Hoffmann-La Roche Ltd, and has stock options in F. Hoffmann-La Roche Ltd. CC and SC are employees of F. Hoffmann-La Roche Ltd, and have stocks in F. Hoffmann-La Roche Ltd. JS, JN, KS, and LM are employees of F. Hoffmann-La Roche Ltd and have stocks and stock options in F. Hoffmann-La Roche Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}